TY - JOUR
T1 - Validation of the WATCH-DM and TRS-HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes
T2 - A Multicohort Analysis
AU - Segar, Matthew W.
AU - Patel, Kershaw V.
AU - Hellkamp, Anne S.
AU - Vaduganathan, Muthiah
AU - Lokhnygina, Yuliya
AU - Green, Jennifer B.
AU - Wan, Siu Hin
AU - Kolkailah, Ahmed A.
AU - Holman, Rury R.
AU - Peterson, Eric D.
AU - Kannan, Vaishnavi
AU - Willett, Duwayne L.
AU - McGuire, Darren K.
AU - Pandey, Ambarish
N1 - Publisher Copyright:
© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2022/6/7
Y1 - 2022/6/7
N2 - BACKGROUND: The WATCH-DM (weight [body mass index], age, hypertension, creatinine, high-density lipoprotein cholesterol, diabetes control [fasting plasma glucose], ECG QRS duration, myocardial infarction, and coronary artery bypass grafting) and TRS-HFDM (Thrombolysis in Myocardial Infarction [TIMI] risk score for heart failure in diabetes) risk scores were developed to predict risk of heart failure (HF) among individuals with type 2 diabetes. WATCH-DM was developed to predict incident HF, whereas TRS-HFDM predicts HF hospitalization among patients with and without a prior HF history. We evaluated the model performance of both scores to predict incident HF events among patients with type 2 diabetes and no history of HF hospitalization across different cohorts and clinical settings with varying baseline risk. METHODS AND RESULTS: Incident HF risk was estimated by the integer-based WATCH-DM and TRS-HFDM scores in participants with type 2 diabetes free of baseline HF from 2 randomized clinical trials (TECOS [Trial Evaluating Cardiovascular Outcomes With Sitagliptin], N=12 028; and Look AHEAD [Look Action for Health in Diabetes] trial, N=4867). The integer-based WATCH-DM score was also validated in electronic health record data from a single large health care system (N=7475). Model discrimination was assessed by the Harrell concordance index and calibration by the Greenwood-Nam-D’Agostino statistic. HF incidence rate was 7.5, 3.9, and 4.1 per 1000 person-years in the TECOS, Look AHEAD trial, and electronic health record cohorts, respectively. Integer-based WATCH-DM and TRS-HFDM scores had similar discrimination and calibration for predicting 5-year HF risk in the Look AHEAD trial cohort (concordance indexes=0.70; Greenwood-Nam-D’Agostino P>0.30 for both). Both scores had lower discrimination and underpredicted HF risk in the TECOS cohort (concordance indexes=0.65 and 0.66, respectively; Greenwood-Nam-D’Agostino P<0.001 for both). In the electronic health record cohort, the integerbased WATCH-DM score demonstrated a concordance index of 0.73 with adequate calibration (Greenwood-Nam-D’Agostino P=0.96). TRS-HFDM score could not be validated in the electronic health record because of unavailability of data on urine albumin/creatinine ratio in most patients in the contemporary clinical practice. CONCLUSIONS: The WATCH-DM and TRS-HFDM risk scores can discriminate risk of HF among intermediate-risk populations with type 2 diabetes.
AB - BACKGROUND: The WATCH-DM (weight [body mass index], age, hypertension, creatinine, high-density lipoprotein cholesterol, diabetes control [fasting plasma glucose], ECG QRS duration, myocardial infarction, and coronary artery bypass grafting) and TRS-HFDM (Thrombolysis in Myocardial Infarction [TIMI] risk score for heart failure in diabetes) risk scores were developed to predict risk of heart failure (HF) among individuals with type 2 diabetes. WATCH-DM was developed to predict incident HF, whereas TRS-HFDM predicts HF hospitalization among patients with and without a prior HF history. We evaluated the model performance of both scores to predict incident HF events among patients with type 2 diabetes and no history of HF hospitalization across different cohorts and clinical settings with varying baseline risk. METHODS AND RESULTS: Incident HF risk was estimated by the integer-based WATCH-DM and TRS-HFDM scores in participants with type 2 diabetes free of baseline HF from 2 randomized clinical trials (TECOS [Trial Evaluating Cardiovascular Outcomes With Sitagliptin], N=12 028; and Look AHEAD [Look Action for Health in Diabetes] trial, N=4867). The integer-based WATCH-DM score was also validated in electronic health record data from a single large health care system (N=7475). Model discrimination was assessed by the Harrell concordance index and calibration by the Greenwood-Nam-D’Agostino statistic. HF incidence rate was 7.5, 3.9, and 4.1 per 1000 person-years in the TECOS, Look AHEAD trial, and electronic health record cohorts, respectively. Integer-based WATCH-DM and TRS-HFDM scores had similar discrimination and calibration for predicting 5-year HF risk in the Look AHEAD trial cohort (concordance indexes=0.70; Greenwood-Nam-D’Agostino P>0.30 for both). Both scores had lower discrimination and underpredicted HF risk in the TECOS cohort (concordance indexes=0.65 and 0.66, respectively; Greenwood-Nam-D’Agostino P<0.001 for both). In the electronic health record cohort, the integerbased WATCH-DM score demonstrated a concordance index of 0.73 with adequate calibration (Greenwood-Nam-D’Agostino P=0.96). TRS-HFDM score could not be validated in the electronic health record because of unavailability of data on urine albumin/creatinine ratio in most patients in the contemporary clinical practice. CONCLUSIONS: The WATCH-DM and TRS-HFDM risk scores can discriminate risk of HF among intermediate-risk populations with type 2 diabetes.
KW - diabetes
KW - heart failure
KW - risk prediction
KW - risk score
KW - Creatinine
KW - Myocardial Infarction/epidemiology
KW - Humans
KW - Risk Factors
KW - Heart Failure/complications
KW - Hospitalization
KW - Diabetes Mellitus, Type 2/complications
KW - Adult
KW - Risk Assessment/methods
UR - http://www.scopus.com/inward/record.url?scp=85132286939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132286939&partnerID=8YFLogxK
U2 - 10.1161/JAHA.121.024094
DO - 10.1161/JAHA.121.024094
M3 - Article
C2 - 35656988
AN - SCOPUS:85132286939
SN - 2047-9980
VL - 11
SP - e024094
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 11
M1 - e024094
ER -